Abrocitinib 100 mg versus 200 mg for atopic dermatitis:
a meta-analysis of randomized controlled trials

Junqiao Wang; Yuanjuan Yang; Haitao Yang; Xiaojuan Fu

doi:10.5114/ada.2022.114925

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2022
vol. 39

Send email

Copy url:

abstract:

Original paper

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials

Junqiao Wang

¹

,

Yuanjuan Yang

²

,

Haitao Yang

³

,

Xiaojuan Fu

²

Wenzhou Peace Plastic Surgery Hospital, Wenzhou, China
Chongqing Medical and Pharmaceutical College, Chongqing, China
Lunan Pharmaceutical Group Co., LTD

Adv Dermatol Allergol 2022; XXXIX (5): 908-912

DOI: https://doi.org/10.5114/ada.2022.114925

Online publish date: 2022/03/27

View full text Get citation

Introduction
It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis.

Aim
This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis.

Material and methods
Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis.

Results
Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39–2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60–2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27–3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11–1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25–1.37; p = 0.22).

Conclusions
Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis.

keywords:

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials

Junqiao Wang 1 , Yuanjuan Yang 2 , Haitao Yang 3 , Xiaojuan Fu 2

abrocitinib, 100 mg, 200 mg, atopic dermatitis, randomized controlled trials

Junqiao Wang

¹

,

Yuanjuan Yang

²

,

Haitao Yang

³

,

Xiaojuan Fu

²